

January 29, 2026

To,
The Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 500672

Subject: Clarification regarding incorrect financial figures of Novartis India Limited (“the Company”) for Q3 2025-26 reported in the Free Press Journal article dated January 28, 2026.

Dear Sir / Madam,

This is to bring to your attention that an article published in the Free Press Journal yesterday, i.e., January 28, 2026, at 3:04 PM, disclosed certain incorrect financial figures pertaining to the quarter ended December 31, 2025, of the Company.

We wish to clarify that the financial information mentioned in the said article is inaccurate and has not been released, verified, or endorsed by the Company. Furthermore, we would like to inform you that the Company has taken appropriate measures to notify the Free Press Journal about the mistake. The Free Press Journal has removed the aforementioned article from their E-Newspaper, and the article now stands withdrawn.

We request the Bombay Stock Exchange, investors, shareholders, and the public at large to refer only to the financial results and disclosures officially published:

- On the website of BSE Limited (<https://www.bseindia.com/stock-share-price/novartis-india-ltd/novartind/500672/corp-announcements/>)
- On the Company's official website (https://www.novartis.com/in-en/sites/novartis_in/files/Financial%20Results%20-%20January%202028%2C%202026.pdf)
- In the newspaper advertisements published today, i.e., January 29, 2026, in the Financial Express on page no. 4 and Navshakti on page no. 9.

We trust the above clarifies the matter.

Thank you.

Yours sincerely,
For **Novartis India Limited**

Chandni Maru
Company Secretary and Compliance Officer
A60291